IFM Investors Pty Ltd Raises Stock Holdings in Illumina, Inc. (NASDAQ:ILMN)

IFM Investors Pty Ltd boosted its stake in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 11.4% during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 32,372 shares of the life sciences company's stock after acquiring an additional 3,309 shares during the quarter. IFM Investors Pty Ltd's holdings in Illumina were worth $2,568,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Capital World Investors grew its stake in Illumina by 408.6% in the 4th quarter. Capital World Investors now owns 18,025,301 shares of the life sciences company's stock valued at $2,408,721,000 after acquiring an additional 14,481,232 shares during the period. WCM Investment Management LLC lifted its holdings in Illumina by 1.2% in the 1st quarter. WCM Investment Management LLC now owns 4,179,011 shares of the life sciences company's stock valued at $334,321,000 after purchasing an additional 49,156 shares in the last quarter. Brown Advisory Inc. lifted its holdings in Illumina by 54,220.9% in the 4th quarter. Brown Advisory Inc. now owns 1,912,639 shares of the life sciences company's stock valued at $255,586,000 after purchasing an additional 1,909,118 shares in the last quarter. Norges Bank purchased a new position in Illumina in the 4th quarter valued at $228,714,000. Finally, Northern Trust Corp lifted its holdings in Illumina by 26.9% in the 4th quarter. Northern Trust Corp now owns 1,652,935 shares of the life sciences company's stock valued at $220,882,000 after purchasing an additional 349,878 shares in the last quarter. Institutional investors and hedge funds own 89.42% of the company's stock.

Illumina Price Performance

ILMN stock traded up $2.12 on Tuesday, reaching $99.27. 1,894,815 shares of the company's stock were exchanged, compared to its average volume of 2,412,066. The stock has a fifty day moving average of $85.44 and a 200-day moving average of $96.95. Illumina, Inc. has a twelve month low of $68.70 and a twelve month high of $156.66. The firm has a market cap of $15.71 billion, a PE ratio of -16.35, a P/E/G ratio of 1.98 and a beta of 1.36. The company has a quick ratio of 1.48, a current ratio of 1.86 and a debt-to-equity ratio of 0.63.

Illumina (NASDAQ:ILMN - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The life sciences company reported $0.97 earnings per share for the quarter, topping analysts' consensus estimates of $0.96 by $0.01. The firm had revenue of $1.04 billion for the quarter, compared to analyst estimates of $1.03 billion. Illumina had a positive return on equity of 25.54% and a negative net margin of 22.25%. Illumina's quarterly revenue was down 1.4% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.98 earnings per share. As a group, equities analysts predict that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CFO Ankur Dhingra bought 6,100 shares of the stock in a transaction on Monday, May 12th. The shares were bought at an average price of $81.21 per share, with a total value of $495,381.00. Following the completion of the acquisition, the chief financial officer owned 24,906 shares of the company's stock, valued at approximately $2,022,616.26. This trade represents a 32.44% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 0.17% of the company's stock.

Analysts Set New Price Targets

A number of brokerages have weighed in on ILMN. Piper Sandler decreased their price objective on Illumina from $190.00 to $185.00 and set an "overweight" rating on the stock in a report on Thursday, May 15th. Royal Bank Of Canada decreased their price objective on Illumina from $128.00 to $112.00 and set an "outperform" rating on the stock in a report on Tuesday, April 8th. JPMorgan Chase & Co. decreased their price objective on Illumina from $120.00 to $85.00 and set a "neutral" rating on the stock in a report on Friday, May 9th. Canaccord Genuity Group raised their price objective on Illumina from $87.00 to $99.00 and gave the company a "hold" rating in a report on Wednesday, June 11th. Finally, Evercore ISI lifted their price target on Illumina from $116.00 to $128.00 and gave the stock an "outperform" rating in a report on Tuesday. One investment analyst has rated the stock with a sell rating, nine have given a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Illumina currently has a consensus rating of "Moderate Buy" and an average target price of $127.42.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.